AR048306A1 - Derivados de acidos carboxilicos aromaticos con capacidad moduladora de los niveles de insulina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de trastornos metabolicos que responden a la regulacion de gpr40 - Google Patents
Derivados de acidos carboxilicos aromaticos con capacidad moduladora de los niveles de insulina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de trastornos metabolicos que responden a la regulacion de gpr40Info
- Publication number
- AR048306A1 AR048306A1 ARP050100748A ARP050100748A AR048306A1 AR 048306 A1 AR048306 A1 AR 048306A1 AR P050100748 A ARP050100748 A AR P050100748A AR P050100748 A ARP050100748 A AR P050100748A AR 048306 A1 AR048306 A1 AR 048306A1
- Authority
- AR
- Argentina
- Prior art keywords
- acid
- phenyl
- alkylene
- alkyl
- hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Abstract
Composiciones farmacéuticas que los contienen y uso de éstos compuestos, por ejemplo, para el tratamiento de la diabetes de tipo II. Reivindicacion 1: Un compuesto caracterizado porque tiene la formula: Q-L1-P-L2-M-X-L3-A, o una de sus sales, solvatos o profármacos farmacéuticamente aceptables, en donde: Q es hidrogeno, arilo, heteroarilo, alquilo C1-6 o heteroalquilo C2-6; L1 es un enlace, alquileno C1-4, heteroalquileno C2-4, O, S(O)m, N(R1), C(O)-heterocicloalquilenoC5-7, alquilenC1-4- SO2N(R2), alquilenC1-4-N(R2)SO2 o C(O)N(R2); P es un anillo aromático, un anillo heteroaromático, heterocicloalquileno C3-8 cicloalquileno C3-8; L2 es un enlace, alquileno C1-6, heteroalquileno C2-6, oximetileno, O, S(O)m, N(R1), C(O)N(R2), SO2N(R2), alquilenC1-4-C(O)N(R2), alquilenC1-4-N(R2)C(O), alquilenC2-4-C(O)N(R2), alquilenC2-4-N(R2)C(O), alquilenC1-4-SO2N(R2), alquilenC1-4-N(R2)SO2, alquilenC2-4-SO2N(R2) o alquilenC2-4-N(R2)SO2; M es un anillo aromático, un anillo heteroaromático, cicloalquileno C5-8, arilalquileno C1-4 o heteroarilalquileno C1-4; X es CR3R4, N(R5), O o S(O)n; L3 es enlace, alquileno C1-3 o heteroalquileno C2-5, con la condicion de que L3 no sea un enlace cuando L2 es un enlace; A es -CO2H, tetrazol-5-ilo, -SO3H, -PO3H2, -SO2NH2, -C(O)NHSO2CH3, -CHO, -C(O)R6, -C(O)NHR6, -C(O)NHOR7, tiazolidindion-ilo, hidroxifenilo o piridilo; R1 es alquilo C1-6, arilalquilo C1-3 o heteroalquilo C2-6; R2 es hidrogeno, alquilo C1-6 o heteroalquilo C1-6; R3 es ciano, arilo, heteroarilo, alquilo C1-8, alquilo C2-8, alquenilo C2-8, alquenilo C3-8, alquinilo C2-8, alquinilo C3-8, -NR8R9, -C(O)NR10R11, -NR12C(O)R13 o -NR12S(O)pR13; R4 es hidrogeno, ciano, arilo, hetearilo, alquilo C1-8, alquenilo C2-8 o alquinilo C2-8; opcionalmente, R3 y R4 se combinan para formar un anillo de 3, 4, 5, 6 o 7 miembros que contiene de cero a tres heteroátomos seleccionados de N, O y S; R5 es hidrogeno, arilo, heteroarilo, alquilo C1-8, alquenilo C2-8, alquinilo C2-8 o cicloalquilo C3-8; R6 es heteroarilo; R7 es hidrogeno o alquilo C1-5; R8 y R9 son independientemente hidrogeno, alquilo C1-5, oxialquilo C1-5; o carboxialquilo C1-5; opcionalmente, R8 y R9 se combinan para formar un anillo de 4, 5, 6 o 7 miembros que contiene el átomo de nitrogeno al que están unidos y de 0 a 2 heteroátomos adicionales seleccionados de N, O y S; R10, R11, y R12 se seleccionan independientemente de hidrogeno, arilo, heteroarilo, alquilo C1-8, heteroalquilo C2-8, cicloalquilo C3-8 y heterocicloalquilo C3-8; opcionalmente, R10 y R11 se combinan para formar un anillo de 4, 5, 6 o 7 miembros que contiene el átomo de nitrogeno al cual están unidos y de 0 a 2 heteroátomos adicionales seleccionados de N, O y S; R13 es arilo, heteroarilo, alquilo C1-8, heteroalquilo C2-8, cicloalquilo C3-8 o heterocicloalquilo C3-8; los subíndices m y n son independientemente 0, 1 o 2; y el subíndice p es 1 o 2; y en donde el compuesto es distinto de ácido 3-(4-(4- metoxibenciloxi)fenil)pent-4-inoico; ácido beta-etenil-4-fenilmetoxi-bencenpropanoico; ácido 4-(2-quinolinilmetoxi)-beta-[4-(2-quinolinilmetoxi)fenil]-bencenpropanoico; N-[4-(benzoilamino)fenil]-N-fenil-glicina; 3-(4-(isopentiloxi)benzamido)-3- fenilpropanoato; 3-(4-isobutoxibenzamido)-3-fenilpropanoato; ácido (R)-2-((1R,4R)-4-isopropilciclohexancarboxamido)-3-fenilpropanoico; ácido (R)-3-(4-(benciloxi)fenil)-2-(ter-butoxicarbonil)propanoico; ácido 3-(4-clorofenil)-3-(furan-2- carboxamido)propanoico; ácido 3-(3,4-dimetoxifenil)-3-(furan-2-carboxamido)propanoico; ácido 3-(4-clorobenzamido)-3-(4-(dimetilamino)-fenil)propanoico; ácido 3-(2-(2-(3,4-dimetilfenoxi)etiltio)-1H-benzo[d]imidazol-1-il)propanoico; ácido {2-bromo-4- [(3,4-dicloro-fenil)hidrazonometil]-6-etoxi-fenoxi}-acético; ácido 2-(4-(2-(2-(4-clorofenil)furan-5-carboxamido)etil)fenoxi)-2-metilpropanoico; ácido 5-(3-(3,4-dimetoxifenil)-5-(2-fluorofenil)-4,5-dihidropirazol-1-il)-5-oxopentanoico; ácido 2-(2-(3- (3,4-dihidro-2H-benzo[d][1,4]dioxepin-7-il)-2-metil-4-oxo-4H-cromen-7-iloxi)acetamido)acético; ácido-3-(4'-bromo-bifenil-4-il)-4-fenil-butírico; ácido 3-(4'-bromo-bifenil-4-il)-3-fenilsulfanil-propionico; ácido 3-(5-(2-cloro-6-fluoro-4- (trifluorometil)-fenoxi)-2,4-dinitrofenil)propanoico; ácido 3-(3-(2-cloro-4-(trifluorometil)fenoxi)fenil)propanoico; ácido 3-(4-(4-metoxibenciloxi)fenil)pent-4-inoico; ácido 3-(4-(4-metoxibenciloxi)fenil)-5-(trimetilsilil)pent-4-inoico; ácido beta,beta-dimetil-4-[[[4-metil-2-[4-(trifluorometil)fenil]-5-tiazolil]metil]tio]-bencenpropanoico; ácido beta-amino-4-[(4-bromo-2,5-dihidro-2-metil-5-oxo-1-fenil-1H-pirazol-3-il)metoxi]-3-metoxi-bencepropanoico; o una de sus sales.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54874104P | 2004-02-27 | 2004-02-27 | |
US60157904P | 2004-08-12 | 2004-08-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR048306A1 true AR048306A1 (es) | 2006-04-19 |
Family
ID=34976072
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050100748A AR048306A1 (es) | 2004-02-27 | 2005-02-28 | Derivados de acidos carboxilicos aromaticos con capacidad moduladora de los niveles de insulina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de trastornos metabolicos que responden a la regulacion de gpr40 |
Country Status (19)
Country | Link |
---|---|
US (2) | US7816367B2 (es) |
EP (1) | EP1737809B1 (es) |
JP (1) | JP5299810B2 (es) |
KR (1) | KR20070004769A (es) |
CN (1) | CN1946666A (es) |
AR (1) | AR048306A1 (es) |
AU (1) | AU2005220728B2 (es) |
BR (1) | BRPI0508098A (es) |
CA (1) | CA2558585C (es) |
CR (1) | CR8642A (es) |
EA (1) | EA011010B1 (es) |
EC (1) | ECSP066887A (es) |
ES (1) | ES2433466T3 (es) |
IL (1) | IL177717A0 (es) |
IS (1) | IS8542A (es) |
MA (1) | MA28466B1 (es) |
NO (1) | NO20064362L (es) |
TW (1) | TW200539854A (es) |
WO (1) | WO2005086661A2 (es) |
Families Citing this family (110)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0319069D0 (en) * | 2003-08-14 | 2003-09-17 | Glaxo Group Ltd | Therapeutically useful compounds |
EA011010B1 (ru) | 2004-02-27 | 2008-12-30 | Эмджен, Инк. | Соединения, модулирующие рецептор gpr40, фармацевтическая композиция, способ лечения заболеваний, чувствительных к модулированию рецептора gpr40 (варианты), способ модулирования функции gpr40 (варианты) и способ модулирования циркулирующей концентрации инсулина |
US7262318B2 (en) * | 2004-03-10 | 2007-08-28 | Pfizer, Inc. | Substituted heteroaryl- and phenylsulfamoyl compounds |
WO2005095338A1 (ja) * | 2004-03-30 | 2005-10-13 | Takeda Pharmaceutical Company Limited | アルコキシフェニルプロパン酸誘導体 |
US20050288340A1 (en) * | 2004-06-29 | 2005-12-29 | Pfizer Inc | Substituted heteroaryl- and phenylsulfamoyl compounds |
CA2593550A1 (en) | 2005-01-07 | 2006-08-10 | Synta Pharmaceutical Corp. | Compounds for inflammation and immune-related uses |
GB0505437D0 (en) * | 2005-03-17 | 2005-04-20 | Merck Sharp & Dohme | Therapeutic agents |
US7465804B2 (en) * | 2005-05-20 | 2008-12-16 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders |
US8097610B2 (en) | 2005-08-26 | 2012-01-17 | Shionogi & Co., Ltd. | Derivative having PPAR agonistic activity |
AU2006291234A1 (en) * | 2005-09-14 | 2007-03-22 | Amgen Inc. | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
ES2348332T3 (es) | 2005-09-16 | 2010-12-02 | Arrow Therapeutics Limited | Derivados de bifenilo y su uso en el tratamiento de la hepatitis c. |
KR100968705B1 (ko) * | 2005-10-27 | 2010-07-06 | 주식회사유한양행 | 신규의 2-페닐피리미딘 유도체 및 그의 제조방법 |
UA95613C2 (ru) * | 2005-11-09 | 2011-08-25 | Уеллстат Терепьютикс Корпорейшн | Соединения для лечения расстройсв метаболизма |
EP1978948A4 (en) * | 2006-02-02 | 2010-06-16 | Wellstat Therapeutics Corp | COMPOUNDS FOR THE TREATMENT OF METABOLISM DISORDER |
AU2007225208A1 (en) * | 2006-03-14 | 2007-09-20 | Amgen Inc. | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders |
TW200815377A (en) | 2006-04-24 | 2008-04-01 | Astellas Pharma Inc | Oxadiazolidinedione compound |
EP2064193A1 (en) * | 2006-09-07 | 2009-06-03 | Amgen, Inc | Heterocyclic gpr40 modulators |
CA2662242C (en) * | 2006-09-07 | 2012-06-12 | Amgen Inc. | Benzo-fused compounds for use in treating metabolic disorders |
US7750048B2 (en) * | 2006-11-15 | 2010-07-06 | Janssen Pharmaceutica Nv | GPR40 agonists |
TW200838526A (en) | 2006-12-01 | 2008-10-01 | Astellas Pharma Inc | Carboxylic acid derivatives |
EA200901099A1 (ru) | 2007-02-22 | 2010-04-30 | Айрм Ллк | Соединения и способы модулирования сопряженных с g-белком рецепторов |
WO2008130514A1 (en) * | 2007-04-16 | 2008-10-30 | Amgen Inc. | Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators |
AU2008311355B2 (en) * | 2007-10-10 | 2012-01-19 | Amgen Inc. | Substituted biphenyl GPR40 modulators |
ME02338B (me) * | 2007-10-26 | 2013-02-28 | Japan Tobacco Inc | Spiro-ciklično jedinjenje i njegova upotreba u medicinske svrhe |
WO2009055932A1 (en) * | 2007-11-02 | 2009-05-07 | Prometic Biosciences Inc. | Substituted phenylpropionic acids as stimulators of hematopoiesis and erythropoiesis |
AU2008326309C1 (en) | 2007-11-21 | 2015-03-12 | Decode Genetics Ehf | Biaryl PDE4 inhibitors for treating pulmonary and cardiovascular disorders |
MX2010009654A (es) * | 2008-03-06 | 2010-09-28 | Amgen Inc | Derivados de acido carboxilico de conformacion restringida utiles para tratar trastornos metabolicos. |
US8633245B2 (en) * | 2008-04-11 | 2014-01-21 | Institute Of Medicinal Molecular Design, Inc. | PAI-1 inhibitor |
CN102137837A (zh) * | 2008-04-11 | 2011-07-27 | 株式会社医药分子设计研究所 | Pai-1抑制剂 |
CA2727340A1 (en) | 2008-06-25 | 2009-12-30 | Daiichi Sankyo Company, Limited | Carboxylic acid compound |
EP2313360B1 (en) | 2008-07-28 | 2012-09-05 | Syddansk Universitet | Compounds for the treatment of metabolic diseases |
EP2358656B1 (en) * | 2008-10-15 | 2014-01-01 | Amgen, Inc | Spirocyclic gpr40 modulators |
CA2740366A1 (en) * | 2008-10-21 | 2010-04-29 | Metabolex, Inc. | Aryl gpr120 receptor agonists and uses thereof |
AR074760A1 (es) | 2008-12-18 | 2011-02-09 | Metabolex Inc | Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico. |
JP2012136438A (ja) * | 2009-04-22 | 2012-07-19 | Astellas Pharma Inc | テトラゾール化合物 |
AR078522A1 (es) | 2009-10-15 | 2011-11-16 | Lilly Co Eli | Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis |
DE102009046115A1 (de) | 2009-10-28 | 2011-09-08 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 3-Phenylpropansäuren und ihre Verwendung |
WO2011052756A1 (ja) | 2009-10-30 | 2011-05-05 | 持田製薬株式会社 | 新規3-ヒドロキシ-5-アリールイソキサゾール誘導体 |
AR078948A1 (es) | 2009-11-30 | 2011-12-14 | Lilly Co Eli | Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes |
EP2332427A1 (en) | 2009-12-07 | 2011-06-15 | Nestec S.A. | low caloric fat replacers |
JP5002077B2 (ja) | 2009-12-25 | 2012-08-15 | 持田製薬株式会社 | 新規3−ヒドロキシ−5−アリールイソチアゾール誘導体 |
US8299117B2 (en) | 2010-06-16 | 2012-10-30 | Metabolex Inc. | GPR120 receptor agonists and uses thereof |
US8530413B2 (en) * | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215388A (en) * | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) * | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
CA2813639A1 (en) | 2010-10-08 | 2012-04-12 | Mochida Pharmaceutical Co. Ltd. | Cyclic amide derivative |
MX2013006053A (es) | 2010-12-07 | 2013-06-18 | Bayer Ip Gmbh | Acidos 1-bencilcicloalquilcarboxilicos sustituidos y su uso. |
GB201104153D0 (en) | 2011-03-11 | 2011-04-27 | Glaxo Group Ltd | Novel compounds |
WO2012136221A1 (en) | 2011-04-08 | 2012-10-11 | Syddansk Universitet | Ortho-fluoro substituted compounds for the treatment of metabolic diseases |
DE102011007272A1 (de) | 2011-04-13 | 2012-10-18 | Bayer Pharma Aktiengesellschaft | Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung |
US8557766B2 (en) | 2011-04-27 | 2013-10-15 | Mochida Pharmaceutical Co., Ltd. | 3-hydroxyisothiazole 1-oxide derivatives |
WO2012147516A1 (ja) | 2011-04-28 | 2012-11-01 | 持田製薬株式会社 | 環状アミド誘導体 |
TWI537262B (zh) * | 2011-08-17 | 2016-06-11 | 美國禮來大藥廠 | 供治療糖尿病使用之新穎1,2,3,4-四氫喹啉衍生物 |
WO2013057743A1 (en) * | 2011-10-21 | 2013-04-25 | Connexios Life Sciences Pvt. Ltd | Process for the preparation of an aryl oxime and salts thereof |
WO2013102626A1 (en) * | 2012-01-04 | 2013-07-11 | Sanofi | 3-[4-(phenylaminooxalylamino)phenyl]hex-4-ynoic acids, process for preparation thereof and use thereof as a medicament |
IN2014MN01839A (es) * | 2012-02-28 | 2015-07-03 | Piramal Entpr Ltd | |
DE102012208530A1 (de) | 2012-05-22 | 2013-11-28 | Bayer Pharma AG | Substituierte Piperidinoacetamide und ihre Verwendung |
AU2013296470B2 (en) | 2012-08-02 | 2016-03-17 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
TWI692469B (zh) * | 2012-11-09 | 2020-05-01 | 南韓商Lg化學股份有限公司 | Gpr40受體促效劑,製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物 |
TW201427971A (zh) | 2012-11-16 | 2014-07-16 | 必治妥美雅史谷比公司 | 二氫吡唑gpr40調節劑 |
MX2015006754A (es) | 2012-12-03 | 2015-08-05 | Hoffmann La Roche | Compuestos de amida de isoxazol sustituido. |
DE102013201104A1 (de) * | 2013-01-24 | 2014-07-24 | H.C. Starck Gmbh | Verfahren zur Herstellung von Chromnitrid-haltigen Spritzpulvern |
RU2015140066A (ru) | 2013-02-22 | 2017-03-30 | Мерк Шарп И Доум Корп. | Противодиабетические бициклические соединения |
CN105209448B (zh) * | 2013-02-28 | 2018-09-14 | 株式会社蒂奥姆生物 | 三环化合物及其用途 |
CN104109115B (zh) * | 2013-04-16 | 2016-11-23 | 中国科学院上海药物研究所 | 一种含氮杂环链接的苯丙酸类化合物、其药物组合物、制备方法和用途 |
WO2014170842A2 (en) | 2013-04-17 | 2014-10-23 | Piramal Enterprises Limited | Substituted alkyl carboxylic acid derivatives as gpr agonists |
KR101569522B1 (ko) * | 2013-04-18 | 2015-11-17 | 현대약품 주식회사 | 신규한 3-(4-(벤질옥시)페닐)헥스-4-이노익 산 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물 |
CN104507921B (zh) * | 2013-07-02 | 2017-02-22 | 四川海思科制药有限公司 | 苯并环丁烯类衍生物、其制备方法及其在医药上的应用 |
CN104418801B (zh) * | 2013-08-19 | 2016-10-05 | 上海润诺生物科技有限公司 | 苯并哌啶环与苯并吗啉环类化合物、其制法及医药应用 |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
IN2013MU03577A (es) | 2013-11-14 | 2015-07-31 | Cadila Healthcare Ltd | |
EP3068768B1 (en) | 2013-11-15 | 2019-07-31 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
EP3076959B1 (en) | 2013-12-04 | 2018-07-04 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
TW201609722A (zh) | 2013-12-13 | 2016-03-16 | 美國禮來大藥廠 | 新穎三唑并吡啶化合物 |
WO2015089809A1 (en) | 2013-12-19 | 2015-06-25 | Merck Sharp & Dohme Corp. | Antidiabetic substituted heteroaryl compounds |
JP6170255B2 (ja) * | 2014-01-10 | 2017-07-26 | イーライ リリー アンド カンパニー | イソプロピルトリアゾロピリジン化合物 |
KR20160095117A (ko) | 2014-01-10 | 2016-08-10 | 일라이 릴리 앤드 캄파니 | 페닐-트리아졸로-피리딘 화합물 |
WO2015119899A1 (en) | 2014-02-06 | 2015-08-13 | Merck Sharp & Dohme Corp. | Antidiabetic compounds |
CA2935897C (en) | 2014-02-19 | 2018-07-03 | Piramal Enterprises Limited | Compounds for use as gpr120 agonists |
WO2015176267A1 (en) | 2014-05-22 | 2015-11-26 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
CA2955919A1 (en) | 2014-07-25 | 2016-01-28 | Piramal Enterprises Limited | Substituted phenyl alkanoic acid compounds as gpr120 agonists and uses thereof |
EP3177285B1 (en) | 2014-08-08 | 2020-09-23 | Merck Sharp & Dohme Corp. | [5,6]-fused bicyclic antidiabetic compounds |
WO2016022742A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
US10662171B2 (en) | 2014-08-08 | 2020-05-26 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2016019587A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [7, 6]-fused bicyclic antidiabetic compounds |
AU2015313829B2 (en) | 2014-09-11 | 2020-07-23 | Piramal Enterprises Limited | Fused heterocyclic compounds as GPR120 agonists |
TW201629033A (zh) | 2014-10-08 | 2016-08-16 | 健生藥品公司 | 作為治療第二型糖尿病之gpr40促效劑的經取代苯并噻吩基衍生物 |
WO2016060517A2 (ko) * | 2014-10-17 | 2016-04-21 | 현대약품 주식회사 | 신규한 3-(4- (벤질옥시)페닐)핵스- 4-이노익 산 유도체 및 다른 유효 성분을 포함하는 대사성 질환의 예방 또는 치료용 복합제제 |
CN107257790A (zh) | 2014-12-18 | 2017-10-17 | 拜耳医药股份有限公司 | 取代的吡啶基‑环烷基‑羧酸、包含它们的组合物及其医学用途 |
US9856245B2 (en) | 2015-08-12 | 2018-01-02 | Janssen Pharmaceutica Nv | GPR40 agonists for the treatment of type II diabetes |
WO2017027310A1 (en) | 2015-08-12 | 2017-02-16 | Janssen Pharmaceutica Nv | Gpr40 agonists for the treatment of type ii diabetes |
US9920040B2 (en) | 2015-08-12 | 2018-03-20 | Janssen Pharmaceutica Nv | GPR40 agonists for the treatment of type II diabetes |
CN105198826A (zh) * | 2015-10-08 | 2015-12-30 | 中国药科大学 | 3,5-二甲基异噁唑类衍生物、其制备方法及其作为药物的用途 |
US10676458B2 (en) | 2016-03-29 | 2020-06-09 | Merch Sharp & Dohne Corp. Rahway | Antidiabetic bicyclic compounds |
US10195178B2 (en) | 2016-04-11 | 2019-02-05 | Janssen Pharmaceutica Nv | GPR40 agonists in anti-diabetic drug combinations |
US10106553B2 (en) | 2016-04-11 | 2018-10-23 | Janssen Pharmaceutica Nv | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes |
CU24576B1 (es) | 2016-05-04 | 2022-02-04 | Centro De Investig Y Desarrollo De Medicamentos Cidem | Compuesto fenólico y combinación del mismo con una benzodiazepina fusionada a 1,4-dihidropiridina para el tratamiento de afecciones del sistema nervioso central y vascular |
US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
KR102007633B1 (ko) | 2016-12-15 | 2019-08-06 | 일동제약(주) | 신규 페닐 프로피온 산 유도체 및 이의 용도 |
WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
CN109666027A (zh) * | 2017-10-17 | 2019-04-23 | 中国科学院上海药物研究所 | 一类酰胺结构的gpr40激动剂化合物及其用途 |
EP3709995A4 (en) | 2017-11-16 | 2021-04-14 | Merck Sharp & Dohme Corp. | BICYCLIC ANTIDIABETIC COMPOUNDS |
AU2019205093B2 (en) * | 2018-01-08 | 2024-03-07 | Celon Pharma S.A. | 3-phenyl-4-hexynoic acid derivatives as GPR40 agonists |
CN110092774B (zh) * | 2018-01-29 | 2022-04-08 | 中国科学院上海药物研究所 | 芳香丙酸类衍生物、及其制备方法和用途 |
US10905667B2 (en) | 2018-07-24 | 2021-02-02 | Bayer Pharma Aktiengesellschaft | Orally administrable modified-release pharmaceutical dosage form |
CN113474335A (zh) | 2019-02-21 | 2021-10-01 | 南京瑞捷医药科技有限公司 | 新型化合物及其作为甲状腺激素受体激动剂的用途 |
JP2023516187A (ja) * | 2020-02-28 | 2023-04-18 | キャリーオペ,インク. | Gpr40アゴニスト |
EP4358958A1 (en) * | 2021-06-21 | 2024-05-01 | Yunovia, Co., Ltd. | Method of controlling blood sugar level and treatment of diabetes and related conditions |
WO2023080299A1 (ko) * | 2021-11-08 | 2023-05-11 | 일동제약(주) | 페닐 프로피온 산 유도체의 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물 |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE305216B (es) | 1965-09-17 | 1968-10-21 | Astra Apotekarnes Kem Fab | |
FR2359135A1 (fr) | 1976-07-22 | 1978-02-17 | Hexachimie | Nouvelles phenoxyhydroxypropylamines, procede pour les preparer et leur application en therapeutique |
US4760089A (en) | 1985-09-09 | 1988-07-26 | Smithkline Beckman Corporation | Irreversible dopamine-β-hydroxylase inhibitors |
PT85081A (en) | 1986-06-19 | 1987-07-01 | Smithkline Beckman Corp | Irreversible dopamine-beta-hydroxylase inhibitors |
GB8917069D0 (en) | 1989-07-26 | 1989-09-13 | Merck Sharp & Dohme | Therapeutic agents |
JPH07508039A (ja) | 1992-05-20 | 1995-09-07 | メルク エンド カンパニー インコーポレーテッド | 4−アザステロイドのエステル誘導体 |
AU668180B2 (en) | 1992-05-20 | 1996-04-26 | Merck & Co., Inc. | 17-ethers and thioethers of 4-aza-steroids |
DE4241632A1 (de) | 1992-12-10 | 1994-06-16 | Thomae Gmbh Dr K | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
US6071970A (en) | 1993-02-08 | 2000-06-06 | Nps Pharmaceuticals, Inc. | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
US5776951A (en) | 1993-06-30 | 1998-07-07 | Glaxo Wellcome Inc. | Anti-atherosclerotic diaryl compounds |
US5463063A (en) | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
EP0799202A1 (de) * | 1994-12-23 | 1997-10-08 | Dr. Karl Thomae GmbH | Piperazinderivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
WO1997003945A1 (en) | 1995-07-14 | 1997-02-06 | Smithkline Beecham Corporation | Substituted-pent-4-ynoic acids |
BR9610624A (pt) | 1995-09-18 | 1999-03-16 | Ligand Pharm Inc | Tratamento de dmndi com agonistas de de rxr |
US5795900A (en) | 1995-10-03 | 1998-08-18 | Abbott Laboratories | Symmetrical bis-heteroaryl-methoxy-phenylalkyl carboxylates as inhibitors of leukotriene biosynthesis |
PT873295E (pt) | 1995-10-06 | 2003-08-29 | Ligand Pharm Inc | Moduladores de rxr selectivos para dimeros para a sua utilizacao |
US5771109A (en) * | 1996-05-17 | 1998-06-23 | Pixar | Method and apparatus for digitizing films using a stroboscopic scanning system |
JPH10316641A (ja) | 1997-03-14 | 1998-12-02 | Sankyo Co Ltd | カルボン酸誘導体 |
WO1999011255A1 (fr) | 1997-08-28 | 1999-03-11 | Ono Pharmaceutical Co., Ltd. | Regulateurs du recepteur active par les agents de proliferation des peroxysomes |
US6645939B1 (en) | 1997-11-24 | 2003-11-11 | Merck & Co., Inc. | Substituted β-alanine derivatives as cell adhesion inhibitors |
WO1999030709A1 (en) | 1997-12-17 | 1999-06-24 | Merck & Co., Inc. | Integrin receptor antagonists |
EP1067109B1 (en) * | 1998-03-10 | 2009-12-09 | Ono Pharmaceutical Co., Ltd. | Carboxylic acid derivatives and drugs containing the same as the active ingredient |
MA26634A1 (fr) | 1998-06-04 | 2004-12-20 | Astra Ab | Nouveaux derives de l'acide 3-aryl propionique et analogues |
DE19941567A1 (de) | 1998-09-05 | 2000-04-20 | Merck Patent Gmbh | Neue flüssigkristalline Verbindungen |
PT1153017E (pt) * | 1999-02-16 | 2006-07-31 | Aventis Pharma Ltd | Compostos biciclicos e sua utilizacao como ligandos do receptor de integrina |
AU3958200A (en) | 1999-04-20 | 2000-11-02 | Novo Nordisk A/S | New compounds, their preparation and use |
ATE323678T1 (de) | 1999-04-28 | 2006-05-15 | Aventis Pharma Gmbh | Tri-aryl-säurederivate als ppar rezeptor liganden |
WO2000068223A1 (en) | 1999-05-05 | 2000-11-16 | Aventis Pharma Limited | Ureas and their use as cell adhesion modulators |
US6262118B1 (en) | 1999-06-04 | 2001-07-17 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia |
GB9914977D0 (en) | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
GB9927056D0 (en) | 1999-11-17 | 2000-01-12 | Karobio Ab | Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders |
US6677473B1 (en) | 1999-11-19 | 2004-01-13 | Corvas International Inc | Plasminogen activator inhibitor antagonists |
JP2001242165A (ja) | 2000-02-25 | 2001-09-07 | Dai Ichi Seiyaku Co Ltd | 採血用試薬 |
JP2002003368A (ja) | 2000-06-23 | 2002-01-09 | Saitama Daiichi Seiyaku Kk | 経皮吸収又は経粘膜吸収用の製剤 |
GB0031107D0 (en) * | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
GB0031527D0 (en) | 2000-12-22 | 2001-02-07 | Smithkline Beecham Plc | New use |
US7238716B2 (en) | 2000-12-28 | 2007-07-03 | Takeda Pharmaceuticals Company Limited | Alkanoic acid derivatives process for their production and use thereof |
TWI311133B (en) | 2001-04-20 | 2009-06-21 | Eisai R&D Man Co Ltd | Carboxylic acid derivativeand the salt thereof |
CZ20033328A3 (cs) * | 2001-06-07 | 2004-06-16 | Eli Lilly And Company | Modulátory receptorů aktivovaných proliferátory peroxisomů (PPAR) |
KR100948278B1 (ko) | 2002-02-07 | 2010-03-18 | 히토시 엔도 | 방향족 아미노산 유도체 및 의약 조성물 |
DE60332320D1 (de) | 2002-02-14 | 2010-06-10 | Takeda Pharmaceutical | Neues screening-verfahren |
US20030207924A1 (en) * | 2002-03-07 | 2003-11-06 | Xue-Min Cheng | Compounds that modulate PPAR activity and methods of preparation |
US6875780B2 (en) | 2002-04-05 | 2005-04-05 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods for their preparation |
WO2003099793A1 (en) | 2002-05-24 | 2003-12-04 | Takeda Pharmaceutical Company Limited | 1,2-azole derivatives with hypoglycemic and hypolipidemic activity |
GB0214149D0 (en) | 2002-06-19 | 2002-07-31 | Glaxo Group Ltd | Chemical compounds |
JP4638735B2 (ja) | 2002-06-24 | 2011-02-23 | タフツ ユニバーシティー | 絹糸生体材料およびその使用方法 |
AU2003261935A1 (en) | 2002-09-06 | 2004-03-29 | Takeda Pharmaceutical Company Limited | Furan or thiophene derivative and medicinal use thereof |
JP4594611B2 (ja) * | 2002-11-08 | 2010-12-08 | 武田薬品工業株式会社 | 受容体機能調節剤 |
AU2003277576A1 (en) * | 2002-11-08 | 2004-06-07 | Takeda Pharmaceutical Company Limited | Receptor function controlling agent |
US20060258683A1 (en) | 2003-04-07 | 2006-11-16 | Liu Kevin | Para-sulfonyl substituted phenyl compounds as modulators of ppars |
US7820837B2 (en) | 2003-05-30 | 2010-10-26 | Takeda Pharmaceutical Company Limited | Condensed ring compound |
WO2005051890A1 (en) | 2003-11-19 | 2005-06-09 | Smithkline Beecham Corporation | Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40 |
AU2004299456B2 (en) | 2003-12-17 | 2010-10-07 | Merck Sharp & Dohme Corp. | (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists |
EP1697339A1 (en) | 2003-12-25 | 2006-09-06 | Takeda Pharmaceutical Company Limited | 3-(4-benzyloxyphenyl)propanoic acid derivatives |
US7585880B2 (en) | 2003-12-26 | 2009-09-08 | Takeda Pharmaceutical Company Limited | Phenylpropanoic acid derivatives |
EA011010B1 (ru) | 2004-02-27 | 2008-12-30 | Эмджен, Инк. | Соединения, модулирующие рецептор gpr40, фармацевтическая композиция, способ лечения заболеваний, чувствительных к модулированию рецептора gpr40 (варианты), способ модулирования функции gpr40 (варианты) и способ модулирования циркулирующей концентрации инсулина |
EP1726580A4 (en) * | 2004-03-15 | 2008-02-13 | Takeda Pharmaceutical | AMINOPHNYLPROPANO ACID DERIVATIVE |
WO2005095338A1 (ja) * | 2004-03-30 | 2005-10-13 | Takeda Pharmaceutical Company Limited | アルコキシフェニルプロパン酸誘導体 |
JP2007269630A (ja) | 2004-06-23 | 2007-10-18 | Toudai Tlo Ltd | インスリン分泌促進剤 |
US20060003344A1 (en) | 2004-06-30 | 2006-01-05 | Pfizer Inc. | Methods related to a single nucleotide polymorphism of the G protein coupled receptor, GPR40 |
JP2007284350A (ja) | 2004-07-27 | 2007-11-01 | Takeda Chem Ind Ltd | 糖尿病治療剤 |
US20080090865A1 (en) | 2005-01-28 | 2008-04-17 | Min Ge | Antidiabetic Bicyclic Compounds |
JP2008528628A (ja) | 2005-01-31 | 2008-07-31 | メルク エンド カムパニー インコーポレーテッド | 抗糖尿病性二環式化合物 |
US7465804B2 (en) | 2005-05-20 | 2008-12-16 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders |
EP2064193A1 (en) * | 2006-09-07 | 2009-06-03 | Amgen, Inc | Heterocyclic gpr40 modulators |
-
2005
- 2005-02-24 EA EA200601388A patent/EA011010B1/ru not_active IP Right Cessation
- 2005-02-24 AU AU2005220728A patent/AU2005220728B2/en not_active Ceased
- 2005-02-24 BR BRPI0508098-3A patent/BRPI0508098A/pt not_active IP Right Cessation
- 2005-02-24 WO PCT/US2005/005815 patent/WO2005086661A2/en active Application Filing
- 2005-02-24 ES ES05723623T patent/ES2433466T3/es active Active
- 2005-02-24 JP JP2007500959A patent/JP5299810B2/ja not_active Expired - Fee Related
- 2005-02-24 EP EP05723623.4A patent/EP1737809B1/en active Active
- 2005-02-24 US US10/591,214 patent/US7816367B2/en active Active
- 2005-02-24 CA CA2558585A patent/CA2558585C/en not_active Expired - Fee Related
- 2005-02-24 CN CNA2005800127092A patent/CN1946666A/zh active Pending
- 2005-02-24 KR KR1020067019713A patent/KR20070004769A/ko not_active Application Discontinuation
- 2005-02-25 US US11/067,377 patent/US7649110B2/en active Active
- 2005-02-28 AR ARP050100748A patent/AR048306A1/es unknown
- 2005-03-01 TW TW094106166A patent/TW200539854A/zh unknown
-
2006
- 2006-08-27 IL IL177717A patent/IL177717A0/en unknown
- 2006-09-13 MA MA29319A patent/MA28466B1/fr unknown
- 2006-09-20 CR CR8642A patent/CR8642A/es not_active Application Discontinuation
- 2006-09-26 NO NO20064362A patent/NO20064362L/no not_active Application Discontinuation
- 2006-09-27 EC EC2006006887A patent/ECSP066887A/es unknown
- 2006-09-27 IS IS8542A patent/IS8542A/is unknown
Also Published As
Publication number | Publication date |
---|---|
CN1946666A (zh) | 2007-04-11 |
US20060004012A1 (en) | 2006-01-05 |
AU2005220728B2 (en) | 2009-08-06 |
IL177717A0 (en) | 2006-12-31 |
AU2005220728A2 (en) | 2005-09-22 |
KR20070004769A (ko) | 2007-01-09 |
EP1737809B1 (en) | 2013-09-18 |
MA28466B1 (fr) | 2007-03-01 |
JP5299810B2 (ja) | 2013-09-25 |
ES2433466T3 (es) | 2013-12-11 |
CA2558585C (en) | 2010-10-12 |
CR8642A (es) | 2008-11-28 |
EA200601388A1 (ru) | 2007-02-27 |
US20070142384A1 (en) | 2007-06-21 |
JP2007525516A (ja) | 2007-09-06 |
CA2558585A1 (en) | 2005-09-22 |
ECSP066887A (es) | 2006-11-24 |
WO2005086661A2 (en) | 2005-09-22 |
EP1737809A2 (en) | 2007-01-03 |
WO2005086661A3 (en) | 2006-05-04 |
IS8542A (is) | 2006-09-27 |
AU2005220728A1 (en) | 2005-09-22 |
NO20064362L (no) | 2006-11-22 |
TW200539854A (en) | 2005-12-16 |
US7816367B2 (en) | 2010-10-19 |
EP1737809A4 (en) | 2007-10-17 |
BRPI0508098A (pt) | 2007-07-17 |
US7649110B2 (en) | 2010-01-19 |
EA011010B1 (ru) | 2008-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR048306A1 (es) | Derivados de acidos carboxilicos aromaticos con capacidad moduladora de los niveles de insulina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de trastornos metabolicos que responden a la regulacion de gpr40 | |
RU2378258C2 (ru) | Производные сульфонамида | |
RU2403247C2 (ru) | Модуляторы никотиновых ацетилхолиновых рецепторов альфа 7 и их терапевтические применения | |
RU2007119427A (ru) | Соединения, являющиеся ингибиторами гликогенфосфорилазы, и фармацевтические композиции на их основе | |
RU2012125372A (ru) | Производные пиразола в качестве ингибиторов 11-бета-hsd1 | |
RU2008129641A (ru) | Ингибиторы ccr9 активности | |
JP2007525516A5 (es) | ||
RU2420522C2 (ru) | Новый класс ингибиторов гистондеацетилаз | |
RU2011110435A (ru) | Пролекарства метилгидрофумарата, фармацетические композиции с ними и способы применения | |
HRP20140201T1 (hr) | Kondenzirani cikliäśki spojevi kao modulatori gpr40-receptora | |
RU2008108984A (ru) | Терапевтический агент от диабета | |
PE20090423A1 (es) | Compuestos moduladores de sirtuina | |
EA201100698A1 (ru) | Производные тиенотриазолодиазепина, активные в отношении апо а1 | |
JP2005514334A5 (es) | ||
CA2435067A1 (en) | Malonyl-coa decarboxylase inhibitors useful as metabolic modulators | |
RU97103207A (ru) | Арилтиосоединения в качестве антибактериальных и противовирусных средств | |
RU99105567A (ru) | Производные пропионовой кислоты и их использование | |
JP2005522438A5 (es) | ||
JP2010526025A5 (es) | ||
JP2014502979A5 (es) | ||
KR920002562A (ko) | 구아니딘 | |
JP2004523490A5 (es) | ||
JP2007502265A5 (es) | ||
JP2010522197A5 (es) | ||
CA2608837A1 (en) | Sulfonamide derivatives useful as liver carnitine palmitoyl transferase (l-cpt1) inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |